Acorda Therapeutics trading halted, volatility trading pause
PremiumThe FlyAcorda Therapeutics trading halted, volatility trading pause
7M ago
Acorda Therapeutics’ Strategic Bankruptcy and Asset Sale Plan
Premium
Company Announcements
Acorda Therapeutics’ Strategic Bankruptcy and Asset Sale Plan
7M ago
Acorda Therapeutics, Merz sign “stalking horse” asset purchase deal for $185M
Premium
The Fly
Acorda Therapeutics, Merz sign “stalking horse” asset purchase deal for $185M
7M ago
Acorda lowers 2023 Inbrija U.S. sales outlook to $34M-$38M from $38M-$42M
PremiumThe FlyAcorda lowers 2023 Inbrija U.S. sales outlook to $34M-$38M from $38M-$42M
1y ago
Acorda Therapeutics reports Q2 EPS ($7.55) vs. ($54.01) last year
Premium
The Fly
Acorda Therapeutics reports Q2 EPS ($7.55) vs. ($54.01) last year
1y ago
Acorda Therapeutics regains compliance with Nasdaq
Premium
The Fly
Acorda Therapeutics regains compliance with Nasdaq
1y ago
Acorda Therapeutics Sees FY23 Ampyra Sales $74.6M – $82.4M
PremiumThe FlyAcorda Therapeutics Sees FY23 Ampyra Sales $74.6M – $82.4M
2y ago
Acorda Therapeutics sees FY23 revenue $122.2M – $135M
Premium
The Fly
Acorda Therapeutics sees FY23 revenue $122.2M – $135M
2y ago
Acorda Therapeutics receives non-compliance letter from NASDAQ
Premium
The Fly
Acorda Therapeutics receives non-compliance letter from NASDAQ
2y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100